Key result
One-year treatment with telmisartan (20-40 mg daily) improved left ventricular mass index, myocardial function, and carotid intima-media thickness in 35 patients with hypertension.
Why the study?
Does telmisartan improve morphologic and functional changes in left ventricular myocardium and carotid arterial wall in previously untreated patients with hypertension?
Does telmisartan improve morphologic and functional changes in left ventricular myocardium and carotid arterial wall in previously untreated patients with hypertension?
Long-term telmisartan monotherapy improves surrogate imaging markers of left ventricular hypertrophy, myocardial function, and carotid atherosclerosis in patients with hypertension.
Answers are grounded in this paper and cite their sources.
May improve subclinical LV and carotid changes in hypertension; leaves open clinical outcome benefits.
OBJECTIVE: The aim of the present study was to clarify the beneficial effects of telmisartan on the morphologic and functional changes in left ventricular (LV) myocardium and carotid arterial wall in patients with hypertension (HT) using tissue Doppler imaging and carotid ultrasonography. METHODS: Telmisartan (20-40 mg daily) was administered to 35 previously untreated patients with HT. Conventional and pulsed tissue Doppler echocardiography were performed after medication had been continued for 1-2 months with normal values for blood pressure (BP) (phase I) and for 12 months (phase II). Subclinical atherosclerosis also was determined by measuring the intima-media thickness (IMT) and stiffness β of the left and right common carotid arteries using B- and M-mode ultrasonography. RESULTS: In the phase II, the LV mass index and isovolumic relaxation time were lower, the peak systolic and early diastolic mitral annular motion velocities were greater compared to the phase I. The stiffness β and mean IMT were lower in the phase II than in the phase I. On multivariate regression analyses, age, BP, and LV diastolic variables emerged as stronger predictors of carotid arterial IMT and stiffness β. CONCLUSIONS: The 1-year use of telmisartan improved LV hypertrophy, regional LV myocardial contraction and relaxation, and carotid atherosclerosis in patients with HT. Our results support cardio- and arterioprotective benefits from continuous long-term telmisartan monotherapy, and combined analysis of tissue Doppler imaging and carotid ultrasonography may be a useful tool for understanding ventriculoarterial coupling in patients with HT.
No takes yet. Share an insight, caveat, or question.
Mizuguchi et al. (2010) studied Hypertension (n=35). Telmisartan vs. Phase I (1-2 months of treatment) was evaluated on Morphologic and functional changes in left ventricular myocardium and carotid arterial wall. One-year treatment with telmisartan (20-40 mg daily) improved left ventricular mass index, myocardial function, and carotid intima-media thickness in 35 patients with hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: